ES2169362T3 - Glicoconjugados de derivados modificados de la camptotecina (union al ciclo a o b). - Google Patents

Glicoconjugados de derivados modificados de la camptotecina (union al ciclo a o b).

Info

Publication number
ES2169362T3
ES2169362T3 ES97910297T ES97910297T ES2169362T3 ES 2169362 T3 ES2169362 T3 ES 2169362T3 ES 97910297 T ES97910297 T ES 97910297T ES 97910297 T ES97910297 T ES 97910297T ES 2169362 T3 ES2169362 T3 ES 2169362T3
Authority
ES
Spain
Prior art keywords
pct
glycoconjugates
camptotechine
union
cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97910297T
Other languages
English (en)
Inventor
Hans-Georg Lerchen
Dem Bruch Karsten Von
Jorg Baumgarten
Michael Sperzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2169362T3 publication Critical patent/ES2169362T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCION TRATA DE GLICOCONJUGADOS DERIVADOS DE CAMPTOTECINA, EN LOS CUALES AL MENOS HAY UNIDO UN COMPONENTE DE CARBOHIDRATO MEDIANTE UN ESPACIADOR O UN SEPARADOR APROPIADO CON UN CICLO DE A O B DE UN DERIVADO DE CAMPTOTECINA. LA INVENCION TRATA ADEMAS DE PROCEDIMIENTOS PARA LA PREPARACION DEL COMPUESTO DE LA INVENCION, ASI COMO SU UTILIZACION COMO MEDICAMENTO, EN PARTICULAR EN RELACION CON ENFERMEDADES CANCERIGENAS.
ES97910297T 1996-09-30 1997-09-17 Glicoconjugados de derivados modificados de la camptotecina (union al ciclo a o b). Expired - Lifetime ES2169362T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19640207A DE19640207A1 (de) 1996-09-30 1996-09-30 Glycokonjugate von modifizierten Camptothecin-Derivaten (A- oder B-Ring-Verknüpfung)

Publications (1)

Publication Number Publication Date
ES2169362T3 true ES2169362T3 (es) 2002-07-01

Family

ID=7807374

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97910297T Expired - Lifetime ES2169362T3 (es) 1996-09-30 1997-09-17 Glicoconjugados de derivados modificados de la camptotecina (union al ciclo a o b).

Country Status (11)

Country Link
US (1) US6156754A (es)
EP (1) EP0939765B1 (es)
JP (1) JP2001506232A (es)
AT (1) ATE210147T1 (es)
AU (1) AU4774897A (es)
CA (1) CA2267493A1 (es)
DE (2) DE19640207A1 (es)
DK (1) DK0939765T3 (es)
ES (1) ES2169362T3 (es)
PT (1) PT939765E (es)
WO (1) WO1998014468A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244701B2 (en) * 2000-06-16 2007-07-17 Zealand Phama A/S Diuretic peptide conjugate
US7550425B2 (en) * 2000-06-16 2009-06-23 Zealand Pharma A/S Diuretic peptide conjugates
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
PL3903829T3 (pl) 2009-02-13 2023-08-14 Immunomedics, Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
KR101639160B1 (ko) * 2015-06-10 2016-07-12 건국대학교 산학협력단 메틸 바이올렛 염료 제거용 벤질 트리아졸 덱스트란 유도체
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US20170224837A1 (en) 2016-02-10 2017-08-10 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
JP7379795B2 (ja) 2016-04-27 2023-11-15 イミューノメディクス、インコーポレイテッド チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果
WO2018183041A1 (en) 2017-03-27 2018-10-04 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
LT3958977T (lt) 2019-04-26 2023-12-27 Immunogen, Inc. Kamptotecino dariniai
KR20230118891A (ko) * 2020-12-11 2023-08-14 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 신규한 캄프토테신 유도체, 이를 포함하는 조성물 및이의 용도
AR125473A1 (es) 2021-04-29 2023-07-19 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
EP0418099B1 (en) * 1989-09-15 2001-12-19 Research Triangle Institute Process of preparation of 10, 11-Methylenedioxy-20 (RS) camptothecin and 10, 11-methylenedioxy-20 (S) - camptothecin analog
CA2087898A1 (en) * 1992-01-24 1993-07-25 Hiroshi Akimoto Condensed heterocyclic compounds, their production and use
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
ES2149867T3 (es) * 1993-02-26 2000-11-16 Drug Delivery System Inst Ltd Derivados de polisacaridos y soportes para farmacos.
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives

Also Published As

Publication number Publication date
DE19640207A1 (de) 1998-04-02
CA2267493A1 (en) 1998-04-09
US6156754A (en) 2000-12-05
EP0939765B1 (de) 2001-12-05
EP0939765A1 (de) 1999-09-08
DK0939765T3 (da) 2002-04-02
JP2001506232A (ja) 2001-05-15
DE59705710D1 (de) 2002-01-17
WO1998014468A1 (de) 1998-04-09
AU4774897A (en) 1998-04-24
PT939765E (pt) 2002-05-31
ATE210147T1 (de) 2001-12-15

Similar Documents

Publication Publication Date Title
ES2169362T3 (es) Glicoconjugados de derivados modificados de la camptotecina (union al ciclo a o b).
BG102616A (en) Substituted aza- and diazacycloheptane and cyclooctane derivatives and their application
MD1838G2 (ro) Derivaţi de 5,6-diclorbenzimidazol, procedeu de obţinere a lor, compoziţie farmaceutică şi metodă de tratament sau de prevenire a infecţiei virotice herpetice
DE69532580D1 (de) Neue antagonistische verbindungen
ES2132415T3 (es) Nuevos derivados de 5-pirrolil-2-piridilmetilsulfinilbencimidazol.
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
PL289487A1 (en) Method of producing new aminophenol derivatives
PT934329E (pt) Glicoconjugados de derivados de camptotecina modificados (ligacao 20-o)
EE03526B1 (et) Leukotrieen-antagonistliku toimega bensopüraanderivaadid, nende valmistamismeetod ja kasutamine
ATE272648T1 (de) Glycokonjugate von 20(s)-camptothecin
KR930702004A (ko) 세파로스포란 산 유도체를 함유하는 정제를 제조하기 위한 직접 압축 방법
IL74138A (en) 4,6,6a,7,8,12b-hexahydro-indolo(4,3-ab)phenanthridines,their production and pharmaceutical compositions containing them
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
KR900007816A (ko) 사이클로프로필-치환된 아졸릴메틸카비놀, 이의 제조방법 및 약제로서의 이의 용도
SE9803107D0 (sv) Novel Compunds
DE60039122D1 (de) 6-o-alkyl-2-nor-2-substituierte ketolidderivate
DK0891322T3 (da) Dimethylsubstituerede cyclohexandienderivater
NZ304823A (en) Beta carboline derivatives and medicaments
ES2119581A1 (es) Utilizacion de fragmentos de timosina y/o sus derivados
ATE179987T1 (de) Vitamin b 12-haltige sanddornkonzentrate oder - extrakte
MX9604201A (es) Nuevos derivados de piperidina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 939765

Country of ref document: ES